Several legislative changes affecting data exclusivity of biologic drugs in Vietnam are poised to come into effect, and companies operating in this sector should take note now, as Hien Thi Thu Vu and Huong Lan Nguyen of Tilleke & Gibbins explain.
Legislative developments surrounding supplementary protection certificates in the EU are moving fast, and may be catching on as far afield as Australia. Gareth Morgan of Olswang explains more.
Following the UK’s vote to leave the EU, it is business as usual for life sciences companies working with intellectual property, at least for now, says Claire Phipps-Jones of Bristows.
The UK’s vote to leave the EU has triggered an immediate need for innovative life sciences companies to evaluate the impact on their patent strategies, argues Laetitia Benard of Allen & Overy.
Is it time for healthcare regulators and patent offices to limit the strategies used by existing biologic manufacturers and allow new suppliers to reach some of the world’s most lucrative healthcare systems? Elizabeth Ward of Virtuoso Legal investigates.
While pharmaceutical companies are more likely to seek patent protection for their inventions, trade secrets can be useful too, particularly following two recent legislative developments, say Andy Sanderson and Ling Zhuang of Potter Clarkson.
The Canadian Intellectual Property Office has updated its guidelines on procedural and examination practices, with some changes affecting biotechnology and medicinal inventions, explain Jason Markwell and Stephanie Anderson of Belmore Neidrauer.
In a recent decision in India, biopharma company Biocon and its partner Mylan were allowed to continue marketing a biosimilar breast cancer drug, as Vikrant Rana and Sanjeeta Das of SS Rana report.
Ahead of the Life Sciences Law Forum 2016, which takes place on June 23 at Etc Venues in the City of London, LSIPR previews some of the main discussion points.
IP and innovation in Mexico has come a long way, and the country’s part in international trade treaties will provide further great opportunities, says Nuria Becerril of Becerril, Coca & Becerril.